Unlocking Metabolism's Potential: Beyond HbA1C, Shielding Hearts, Preserving Kidneys, Exploring NASH.

Type-2 diabetes (T2D) is a prevalent medical condition characterized by insulin resistance, affecting approximately 425 million people worldwide. As diabetes is projected to become a major cause of death by 2030, patients with T2D face a heightened risk of life-threatening health complications, impacting their quality of life and escalating medical care expenses.

Our mission revolves around addressing T2D and other related cardiovascular, renal, and metabolic (CVRM) diseases. Through innovative research, we aim to transform diabetes treatment, advance patient care, and find unique solutions that benefit healthcare systems. Our commitment is to put patients first, striving for earlier responses and preventing severe outcomes to enhance the lives of those affected by metabolic diseases.